Danaher Corporation $DHR Shares Sold by DNB Asset Management AS

DNB Asset Management AS reduced its position in Danaher Corporation (NYSE:DHR) by 3.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 167,492 shares of the conglomerate’s stock after selling 5,271 shares during the period. DNB Asset Management AS’s holdings in Danaher were worth $33,086,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Entropy Technologies LP grew its position in shares of Danaher by 80.9% in the second quarter. Entropy Technologies LP now owns 38,445 shares of the conglomerate’s stock valued at $7,594,000 after purchasing an additional 17,198 shares during the period. Swiss National Bank boosted its stake in Danaher by 6.3% in the 2nd quarter. Swiss National Bank now owns 1,949,208 shares of the conglomerate’s stock worth $385,047,000 after buying an additional 115,900 shares during the last quarter. Marsico Capital Management LLC purchased a new stake in Danaher in the 2nd quarter valued at about $4,999,000. Prudential PLC increased its stake in shares of Danaher by 18.3% during the 2nd quarter. Prudential PLC now owns 81,748 shares of the conglomerate’s stock valued at $16,148,000 after acquiring an additional 12,632 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in shares of Danaher by 9.6% during the 2nd quarter. Howe & Rusling Inc. now owns 34,215 shares of the conglomerate’s stock worth $6,759,000 after acquiring an additional 2,989 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Evercore ISI boosted their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. TD Cowen lifted their price target on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Bank of America cut their target price on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Stock Performance

Shares of NYSE:DHR opened at $227.34 on Friday. The business’s 50-day simple moving average is $208.58 and its 200 day simple moving average is $201.97. The company has a market cap of $160.58 billion, a P/E ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the company earned $1.71 earnings per share. Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is presently 26.39%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 30,248 shares of company stock worth $6,609,663. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.